Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Biological Replicate ID | Conc Unit | GR50 | GEC50 | GRmax | GRinf | GR Hill Coefficient | GR_AOC | GR r2 | Nominal Division Rate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MCF 10F | NM | - | Erlotinib | EGFR | ErbB | 7486.092 | uM | 0.38067 | 0.55409 | -0.3248 | -0.2497 | 1.0790 | 0.3613 | 0.9780 | 1.1266 | |
MCF 10F | NM | - | Erlotinib | EGFR | ErbB | 7487.09 | uM | 0.20420 | 0.24610 | -0.2461 | -0.1722 | 1.5855 | 0.4893 | 0.9936 | 1.5226 | |
MCF 10F | NM | - | Etoposide | TOP2 | TOP | 7487.074 | uM | 0.88720 | 1.10050 | -0.0104 | -0.0526 | 0.4644 | 0.4681 | 0.9833 | 1.4197 | |
MCF 10F | NM | - | Everolimus | MTOR | MTOR | 12254.164 | uM | 1.64590 | 87.8530 | -0.0725 | -1.0000 | 0.2762 | 0.3434 | 0.8749 | 1.4589 | |
MCF 10F | NM | - | Fascaplysin | CDK4 | CDK | 7487.084 | uM | 0.27808 | 0.47257 | -0.9814 | -0.9785 | 2.0446 | 0.6770 | 0.9945 | 1.3396 | |
MCF 10F | NM | - | FR180204 | ERK1/2 | MAPK | 12254.161 | uM | 68.76550 | 85.650 | -0.3684 | -0.9988 | 5.0000 | 0.0561 | 0.9916 | 1.3991 | |
MCF 10F | NM | - | FTase Inhibitor I | Ftase | MAPK | 12254.154 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0451 | -13.9008 | 1.6307 | |
MCF 10F | NM | - | Gefitinib | EGFR | ErbB | 9566.132 | uM | inf | inf | 0.7541 | 0.7541 | 0.0000 | 0.0697 | 0.1447 | 2.4013 | |
MCF 10F | NM | - | Gefitinib | EGFR | ErbB | 7872.016 | uM | 0.80130 | 4.43150 | -0.6400 | -1.0000 | 0.6424 | 0.3653 | 0.9409 | 1.4834 | |
MCF 10F | NM | - | Gefitinib | EGFR | ErbB | 7871.016 | uM | 0.67368 | 0.76579 | -0.3020 | -0.2081 | 2.7155 | 0.3233 | 0.9889 | 1.0272 | |
MCF 10F | NM | - | Gefitinib | EGFR | ErbB | 7488.016 | uM | 0.26856 | 0.42096 | -0.5650 | -0.4649 | 1.4628 | 0.4992 | 0.9915 | 1.2238 | |
MCF 10F | NM | - | Geldanamycin | HSP90 | HSP90 | 9566.012 | uM | 0.00842 | 0.01042 | -0.3693 | -0.3163 | 2.3022 | 0.9250 | 0.9967 | 2.2335 | |
MCF 10F | NM | - | Gemcitabine | DNA replication | DNA replication | 9566.011 | uM | 0.17668 | 0.27477 | -0.0206 | -0.1052 | 0.4323 | 0.5392 | 0.9882 | 2.3358 | |
MCF 10F | NM | - | Glycyl-H-1152 | ROCK2 | 12254.16 | uM | inf | inf | 0.8887 | 0.8887 | 0.0000 | -0.0374 | 0.1921 | 1.4029 | ||
MCF 10F | NM | - | GSK1070916 | AURK | AURK | 7872.001 | uM | 2.2340 | 7.22850 | -0.6879 | -1.0000 | 0.9356 | 0.3511 | 0.9389 | 1.3610 | |
MCF 10F | NM | - | GSK1070916 | AURK | AURK | 7871.001 | uM | 2.23770 | 6.84550 | -0.7729 | -1.0000 | 0.9825 | 0.3279 | 0.9440 | 1.0311 | |
MCF 10F | NM | - | GSK1070916 | AURK | AURK | 9566.001 | uM | 6.56250 | 18.63840 | -0.3303 | -1.0000 | 1.0525 | 0.1920 | 0.9546 | 2.1122 | |
MCF 10F | NM | - | GSK1838705A | IGF1R | RTK | 7487.09 | uM | 0.47729 | 0.68307 | -0.6071 | -0.4816 | 1.8819 | 0.5795 | 0.9918 | 1.5226 | |
MCF 10F | NM | - | GSK1838705A | IGF1R | RTK | 7486.092 | uM | 0.34958 | 0.35779 | -0.1173 | -0.0615 | 4.9990 | 0.4378 | 0.9932 | 1.1266 | |
MCF 10F | NM | - | GSK1838705A | IGF1R | RTK | 7486.098 | uM | 0.78463 | 1.45630 | -0.8091 | -0.8272 | 1.5786 | 0.5257 | 0.9984 | 0.9165 | |
MCF 10F | NM | - | GSK461364 | PLK1 | PLK | 7872.001 | uM | 0.09846 | 2.81320 | -0.8377 | -1.0000 | 0.3277 | 0.5212 | 0.7757 | 1.3610 | |
MCF 10F | NM | - | GSK461364 | PLK1 | PLK | 9566.001 | uM | 0.72853 | 7.71830 | -0.6935 | -1.0000 | 0.4655 | 0.3519 | 0.8104 | 2.1122 | |
MCF 10F | NM | - | GSK461364 | PLK1 | PLK | 7871.001 | uM | 0.00914 | 0.00922 | -0.3389 | -0.0221 | 4.9649 | 0.6278 | 0.9295 | 1.0311 | |
MCF 10F | NM | - | GSK923295 | CENPE | Kinesin | 7872.001 | uM | 0.19755 | 22.5560 | -0.3597 | -1.0000 | 0.2319 | 0.4415 | 0.6126 | 1.3610 | |
MCF 10F | NM | - | GSK923295 | CENPE | Kinesin | 9566.001 | uM | 4.84040 | 99.0590 | 0.0556 | -1.0000 | 0.3639 | 0.2100 | 0.8124 | 2.1122 |